Clinical Trials
18 trialsNCT06692452 2026-04-01
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT06313996 2026-03-18
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
NCT05934097 2023-07-06
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
Fate Therapeutics
Phase 1 Withdrawn
NCT04974996 2022-03-29
LOTIS-8
ADC Therapeutics S.A.
Phase 1 Withdrawn
NCT00006669 2021-10-27
Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma
Medstar Health Research Institute
Phase 2 Withdrawn
NCT02605694 2021-03-17
FRESCO
SecuraBio
Phase 2 Withdrawn
NCT01415765 2019-12-17
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT02538926 2018-11-14
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
University of Washington
Phase 2 Withdrawn
NCT02228512 2018-08-31
Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT00900445 2018-08-07
Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia
Children's Oncology Group
Withdrawn
NCT02815059 2018-01-31
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
University of Utah
Phase 1 Withdrawn
NCT00983944 2017-11-30
Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Withdrawn
NCT02595242 2017-05-23
Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Withdrawn
NCT00513188 2016-12-15
Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma
University of Miami
Phase NA Withdrawn
NCT01539174 2016-03-03
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma
Fox Chase Cancer Center
Phase 2 Withdrawn
NCT00004039 2015-08-19
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
Hoag Memorial Hospital Presbyterian
Phase 2 Withdrawn
NCT00019409 2012-03-23
Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia
National Institutes of Health Clinical Center (CC)
Phase 3 Withdrawn
NCT00110006 2010-06-11
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma
Case Comprehensive Cancer Center
Phase NA Withdrawn